Prescription Drug Information: Meclizine Hydrochloride

MECLIZINE HYDROCHLORIDE- meclizine hydrochloride tablet
Rebel Distributors Corp.

DESCRIPTION

Meclizine hydrochloride, an oral antiemetic, is a white, slightly yellowish, crystalline powder which has a slight odor and is tasteless. It has the following structural formula:

Chemical Structure
(click image for full-size original)
C25 H27 CIN2 •2HCI•H2 O M.W. 481.89

The chemical name is 1-(p -chloro-alpha-phenylbenzyl)-4-(m -methyl-benzyl) — piperazine dihydrochloride monohydrate.

Meclizine Hydrochloride Tablets are available in 12.5 mg, and *25 mg strengths for oral administration.

*Contains FD&C Yellow #5 (see PRECAUTIONS).

Each tablet contains the following inactive ingredients: colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, starch, stearic acid and other ingredients. In addition, the 12.5 mg tablet contains FD&C Blue #1; and the 25 mg tablet contains D&C Yellow #10 and FD&C Yellow #5.

CLINICAL PHARMACOLOGY

Meclizine hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

INDICATIONS AND USAGE

For the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.

CONTRAINDICATIONS

Meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking the drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland. Do not give to children under 12 years of age unless directed by a doctor.

PRECAUTIONS

The Meclizine Hydrochloride Tablets, 25 mg contain FD&C Yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow #5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Usage in Children: Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended under 12 years of age.

Usage in Pregnancy: Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine hydrochloride increases the risk of abnormalities when administered during pregnancy.

Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine hydrochloride, or any other medication should be used during pregnancy only if clearly necessary.

ADVERSE REACTIONS

Drowsiness, dry mouth, and on rare occasions, blurred vision have been reported.

DOSAGE AND ADMINISTRATION

Motion Sickness: The initial dose of 25 to 50 mg meclizine hydrochloride, should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

HOW SUPPLIED

Meclizine Hydrochloride Tablets, USP 12.5 mg — blue, oval tablets debossed with “034” on one side and “par” on the other side. Tablets may contain characteristic dye spots. They are supplied in bottles of 30 (NDC 21695-383-30).

Meclizine Hydrochloride Tablets, USP 25 mg — yellow, oval tablets debossed with “035” on one side and “par” on the other side. They are supplied in bottles of 10 (NDC 21695-237-10), 15 (NDC 21695-237-15), 30 (NDC 21695-237-30), 40 (NDC 21695-237-40) and 90 (NDC 21695-237-90).

Dispense in tight, light-resistant containers as defined in the USP.

Store at controlled room temperature 15°-30°C (59°-86°F).

Manufactured by:

PAR PHARMACEUTICAL COMPANIES, INC.

Spring Valley, NY 10977

Repackaged by:

REBEL DISTRIBUTORS CORP

Thousand Oaks, CA 91320

Principal Display Panel

Meclizine 12.5mg
(click image for full-size original)

MECLIZINE HYDROCHLORIDE
meclizine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:21695-383(NDC:49884-034)
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Meclizine Hydrochloride (Meclizine) Meclizine Hydrochloride 12.5 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE
LACTOSE
Magnesium stearate
CELLULOSE, MICROCRYSTALLINE
SODIUM STARCH GLYCOLATE TYPE A POTATO
STARCH, CORN
Stearic Acid
FD&C BLUE NO. 1
Product Characteristics
Color BLUE Score no score
Shape OVAL Size 5mm
Flavor Imprint Code Par;034
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:21695-383-30 30 TABLET (TABLET) in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA087127 06/03/1981
MECLIZINE HYDROCHLORIDE
meclizine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:21695-237(NDC:49884-035)
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Meclizine Hydrochloride (Meclizine) Meclizine Hydrochloride 25 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE
LACTOSE
Magnesium stearate
CELLULOSE, MICROCRYSTALLINE
SODIUM STARCH GLYCOLATE TYPE A POTATO
STARCH, CORN
Stearic Acid
FD&C YELLOW NO. 5
D&C YELLOW NO. 10
Product Characteristics
Color YELLOW Score no score
Shape OVAL Size 6mm
Flavor Imprint Code Par;035
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:21695-237-10 10 TABLET (TABLET) in 1 BOTTLE None
2 NDC:21695-237-15 15 TABLET (TABLET) in 1 BOTTLE None
3 NDC:21695-237-30 30 TABLET (TABLET) in 1 BOTTLE None
4 NDC:21695-237-40 40 TABLET (TABLET) in 1 BOTTLE None
5 NDC:21695-237-90 90 TABLET (TABLET) in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA087128 06/03/1981
Labeler — Rebel Distributors Corp. (118802834)
Establishment
Name Address ID/FEI Operations
Rebel Distributors Corp. 118802834 RELABEL, REPACK

Revised: 09/2010 Rebel Distributors Corp.

RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

As a leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. RxDrugLabels.com provides the full prescription-only subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2022. All Rights Reserved.